Vega Investment Solutions Acquires Shares of 4,968 IQVIA Holdings Inc. (NYSE:IQV)

Vega Investment Solutions acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 4,968 shares of the medical research company's stock, valued at approximately $976,000. IQVIA makes up approximately 0.8% of Vega Investment Solutions' investment portfolio, making the stock its 27th biggest position.

A number of other institutional investors have also recently bought and sold shares of IQV. Vise Technologies Inc. bought a new stake in shares of IQVIA during the 4th quarter valued at $254,000. Pinkerton Retirement Specialists LLC boosted its stake in shares of IQVIA by 3.4% during the fourth quarter. Pinkerton Retirement Specialists LLC now owns 12,602 shares of the medical research company's stock valued at $2,476,000 after purchasing an additional 414 shares in the last quarter. MidWestOne Financial Group Inc. grew its holdings in IQVIA by 42.2% during the 4th quarter. MidWestOne Financial Group Inc. now owns 6,805 shares of the medical research company's stock worth $1,337,000 after acquiring an additional 2,019 shares during the last quarter. Continuum Advisory LLC increased its holdings in IQVIA by 3.7% in the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock valued at $354,000 after purchasing an additional 64 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of IQVIA by 13.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after acquiring an additional 167,057 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.8%

Shares of NYSE:IQV traded down $1.18 during midday trading on Wednesday, hitting $139.36. 470,190 shares of the company's stock were exchanged, compared to its average volume of 1,561,540. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a market cap of $24.11 billion, a PE ratio of 18.57, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The stock has a 50 day moving average price of $153.47 and a 200-day moving average price of $182.26.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same period in the previous year, the company posted $2.54 EPS. The company's revenue for the quarter was up 2.5% on a year-over-year basis. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. UBS Group decreased their price target on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Barclays lowered their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. cut their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Finally, Robert W. Baird lowered their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.